Search alternatives:
points decrease » point decrease (Expand Search), point increase (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 points » 5 point (Expand Search), _ points (Expand Search), 3 points (Expand Search)
points decrease » point decrease (Expand Search), point increase (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 points » 5 point (Expand Search), _ points (Expand Search), 3 points (Expand Search)
-
141
-
142
-
143
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
Decrease in cell viability by siRNA and miRNA dependent induction of DTA.
Published 2014“…<p>U251 cells were transfected with the indicated construct (50 ng) with (A) or without (B) siRNAs (10pmol). …”
-
154
-
155
-
156
-
157
-
158
-
159
PIN1 silencing leads to decreases in the protein levels of HIF-1α.
Published 2016“…E) ATRA decreases the expression of HIF-1α and PIN1 in HCT116/5xHRE-ODD-luc cells in dose-dependent manner. …”
-
160
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”